Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575927 | 0.88 | EPHX2 (0.64) | EPHX2LMNAGAASSTR4HDAC3 | |
| SCHEMBL14025088 | 0.83 | EPHX2 (0.60) | EPHX2LMNAGAASSTR4HDAC3 | |
| SCHEMBL14004671 | 0.83 | EPHX2 (0.60) | EPHX2LMNAGAASSTR4HDAC3 | |
| SCHEMBL16480210 | 0.83 | EPHX2 (0.60) | EPHX2LMNAGAASSTR4HDAC3 | |
| SCHEMBL2692933 | 0.82 | EPHX2 (0.59) | EPHX2LMNAGAASSTR4HDAC3 | |
| SCHEMBL9514720 | 0.81 | TRPV1 (0.57) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL9513695 | 0.81 | TRPV1 (0.57) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL9515008 | 0.81 | TRPV1 (0.57) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL5106897 | 0.81 | EPHX2 (0.55) | EPHX2LMNAGAASSTR4HDAC3 | |
| SCHEMBL4885710 | 0.81 | EPHX2 (0.55) | EPHX2LMNAGAASSTR4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216950-B2 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-12-22 | — | — | US | disclosed |
| US-9090617-B1 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-07-28 | — | — | US | disclosed |
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | RAND BIOSCIENCES (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20140200239-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | SRC, PTPRCAP, GRB2 | EPHX2 1893/4885LMNA 4875/4885GAA 3678/4885 |
| US-20140200239-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | SRC, PTPRCAP, GRB2 | EPHX2 1893/4885LMNA 4875/4885GAA 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.